Compass Pathways’ Psilocybin Therapy Receives FDA’s Breakthrough Therapy Designation for Treatment-Resistant Depression

 Compass Pathways’ Psilocybin Therapy Receives FDA’s Breakthrough Therapy Designation for Treatment-Resistant Depression

Compass Pathways’ Psilocybin Therapy Receives FDA’s Breakthrough Therapy Designation for Treatment-Resistant Depression

Shots:

  • The FDA’s BT designation follows clinical study assessing Psilocybin in 19 patients with treatment resistant depression, conducted at Imperial College London in 2015
  • FDA’s BT designation is granted to the drugs showing substantial improvement over currently available therapy in serious or life-threatening conditions on at least one clinically significant endpoint with benefits of Priority Review and accelerated approval
  • Psilocybin is a serotonin 2 receptor agonist, being evaluated in a clinical study for treatment-resistant depression in EU and North America

Click here to read full press release/ article | Ref: Compass Pathway | Image: Compass Pathway

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post